ABVC BioPharma (NASDAQ:ABVC) Earns Sell (E+) Rating from Weiss Ratings

ABVC BioPharma (NASDAQ:ABVC)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

ABVC BioPharma Price Performance

NASDAQ ABVC opened at $2.98 on Friday. The company has a market cap of $70.15 million, a P/E ratio of -17.53 and a beta of 0.30. The stock has a 50-day moving average of $2.95 and a two-hundred day moving average of $2.36. ABVC BioPharma has a 1-year low of $0.40 and a 1-year high of $5.48.

ABVC BioPharma (NASDAQ:ABVC) last released its earnings results on Wednesday, August 13th. The company reported ($0.13) earnings per share for the quarter.

Hedge Funds Weigh In On ABVC BioPharma

A hedge fund recently raised its stake in ABVC BioPharma stock. XTX Topco Ltd lifted its stake in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) by 75.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 60,439 shares of the company’s stock after buying an additional 26,034 shares during the quarter. XTX Topco Ltd owned approximately 0.36% of ABVC BioPharma worth $64,000 at the end of the most recent reporting period. 11.38% of the stock is currently owned by hedge funds and other institutional investors.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.